Drugs / REX-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03174522 | Apr 2017 → Feb 2023 | limb ischemia, peripheral arterial disease, type 1 diabetes mellitus, type 2 diabetes mellitus | Ixaka Ltd | Terminated | No outcome recorded |
| Phase 3 | NCT03111238 | Apr 2017 → Mar 2021 | limb ischemia, peripheral arterial disease, type 1 diabetes mellitus, type 2 diabetes mellitus | Ixaka Ltd | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REX-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03174522 ↗ |
| Modality | Cell therapy | “REX-001 is a cell suspension of autologous BM-MNCs composed of several mature cell types.” NCT03111238 ↗ |
| Route | Other | “REX-001 is administered through an intra-arterial catheter.” NCT03111238 ↗ |